Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
U.S. activists unveil a national action plan to #BreakThePatent. It points out that taxpayers funded the research behind Truvada as PrEP.
Stocks of drug companies are rising—and that’s not a good sign for consumers.
A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.
The FDA commissioner wants drugmakers to “end the shenanigans.”
This marks the manufacturer’s fifth generic antiretroviral launch.
AIDS activists urge the N.Y. attorney general to investigate possible antitrust violations regarding the HIV med used as PrEP.
The company is losing its exclusive rights to two HIV drugs: Reyataz and Sustiva.
However, Gilead Sciences, the brand-name manufacturer of Truvada, insists a generic version “will not be immediately available.”
Scott Gottlieb has said he wants lower costs and faster drug approvals.
The switch doesn’t appear to compromise the efficacy of antiretroviral treatment.
The country supplies generic meds to much of the world—but thanks to a new law, not for its own citizens living with HIV.
But do Scott Gottlieb’s interests lie with drugmakers or patients?
PolitiFact and Africa Check look into a conservative website’s accusations.
“We need drugs that are gentler, kinder, better and cheaper.”
“Feeling used and abused by the Sanders campaign right now,” writes Peter Staley.
Researchers are launching trials of a $300 generic hepatitis C regimen that could help expand treatment of the virus in poorer nations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.